Report Open Access

Best-practice guidance for the health technology assessment of diagnostics and treatments for COVID-19

Elvidge, Jamie; Summerfield, Ashley; Knies, Saskia; Németh, Bertalan; Kaló, Zoltán; Goettsch, Wim; Dawoud, Dalia


DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.5281/zenodo.5530468</identifier>
  <creators>
    <creator>
      <creatorName>Elvidge, Jamie</creatorName>
      <givenName>Jamie</givenName>
      <familyName>Elvidge</familyName>
      <affiliation>1. Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE)</affiliation>
    </creator>
    <creator>
      <creatorName>Summerfield, Ashley</creatorName>
      <givenName>Ashley</givenName>
      <familyName>Summerfield</familyName>
      <affiliation>2.	Medicines Analysis, NHS England and NHS Improvement, UK</affiliation>
    </creator>
    <creator>
      <creatorName>Knies, Saskia</creatorName>
      <givenName>Saskia</givenName>
      <familyName>Knies</familyName>
      <affiliation>3.	National Health Care Institute (Zorginstituut Nederland), Netherlands</affiliation>
    </creator>
    <creator>
      <creatorName>Németh, Bertalan</creatorName>
      <givenName>Bertalan</givenName>
      <familyName>Németh</familyName>
      <affiliation>4.	Syreon Institute, Hungary</affiliation>
    </creator>
    <creator>
      <creatorName>Kaló, Zoltán</creatorName>
      <givenName>Zoltán</givenName>
      <familyName>Kaló</familyName>
      <affiliation>4.	Syreon Institute, Hungary</affiliation>
    </creator>
    <creator>
      <creatorName>Goettsch, Wim</creatorName>
      <givenName>Wim</givenName>
      <familyName>Goettsch</familyName>
      <affiliation>3.	National Health Care Institute (Zorginstituut Nederland), Netherlands,5.	Utrecht Centre for Pharmaceutical Policy, Utrecht University, Netherlands</affiliation>
    </creator>
    <creator>
      <creatorName>Dawoud, Dalia</creatorName>
      <givenName>Dalia</givenName>
      <familyName>Dawoud</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0002-2105-1937</nameIdentifier>
      <affiliation>1. Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE)</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Best-practice guidance for the health technology assessment of diagnostics and treatments for COVID-19</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2021</publicationYear>
  <subjects>
    <subject>Health Technology Assessment (HTA)</subject>
    <subject>COVID-19</subject>
    <subject>Diagnostics</subject>
    <subject>Treatments</subject>
    <subject>Clinical effectiveness</subject>
    <subject>Cost effectiveness</subject>
    <subject>Value Framework</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2021-09-27</date>
  </dates>
  <language>en</language>
  <resourceType resourceTypeGeneral="Report"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/5530468</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.5530467</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/covid-19</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;To support HTA agencies with consistent and pragmatic approaches, we have developed this best-practice guidance for the assessment of technologies for COVID-19. We focused on diagnostic and therapeutic technologies, as the most commonly assessed by HTA agencies. For therapeutics, we focused on treatments rather than post-exposure prophylaxis, however, the recommended approach is unlikely to be much different for prophylactic options.&lt;/p&gt;

&lt;p&gt;The recommendations herein are based on findings from a survey and workshop of HTA agencies, a workshop with health economic modellers, and reviews of COVID-19 methods guidance, clinical guidelines, and economic evaluations. They have also been discussed with, and refined with input from, a multi-stakeholder group at a policy sandbox event. The recommendations span several themes relevant to HTA, and some of the key proposals are summarised below. Foremost among them is the recommendation that the pandemic is used as an opportunity to implement a responsive, &amp;ldquo;living&amp;rdquo; approach to HTA.&lt;/p&gt;</description>
  </descriptions>
  <fundingReferences>
    <fundingReference>
      <funderName>European Commission</funderName>
      <funderIdentifier funderIdentifierType="Crossref Funder ID">10.13039/501100000780</funderIdentifier>
      <awardNumber awardURI="info:eu-repo/grantAgreement/EC/H2020/825162/">825162</awardNumber>
      <awardTitle>Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe</awardTitle>
    </fundingReference>
  </fundingReferences>
</resource>
950
486
views
downloads
All versions This version
Views 950950
Downloads 486486
Data volume 585.5 MB585.5 MB
Unique views 844844
Unique downloads 432432

Share

Cite as